Laurion Capital Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Laurion Capital Management's AXSM Position: Q3 2026 in Review
Laurion Capital Management increased its Axsome Therapeutics (AXSM) stake by 25% in Q3 2026, buying an estimated $62.2K and bringing the position to 1,441 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #376.
Laurion Capital Management first reported a position in AXSM in Q1 2019 and has held it in 3 quarters since. The position peaked at $3.12M in Q1 2019. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Laurion Capital Management held 1,441 shares of Axsome Therapeutics worth $266K as of Q3 2026.
- Laurion Capital Management bought 286 Axsome Therapeutics shares in Q3 2026, an estimated $62.2K.
- Axsome Therapeutics made up ﹤0.01% of Laurion Capital Management's portfolio in Q3 2026, its #376 holding.
- Laurion Capital Management first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 3 quarters since.
- Laurion Capital Management's Axsome Therapeutics position peaked at $3.12M in Q1 2019.
- 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Laurion Capital Management's 13F filing for Q3 2026, filed 30 Oct 2026.